Based upon our observations, we next investigated the impact of targeting T cell checkpoints on tumor growth by using anti-TIM3, anti-TIGIT, anti-LAG3, or anti-CTLA4, alone or in combination with anti-PD-1. This evidence concerns the gene PDCD1 and neoplasm.